Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome

American Heart Journal

Volumn 151, Issue 5, 2006, Pages 1102-1107

  Smit, Jaap Jan J ^a   Ernst, Nicolette M S K J ^a   Slingerland, Robbert J ^a   Kolkman, J J Evelien ^a   Suryapranata, Harry ^a   Hoorntje, Jan C A ^a   Dambrink, Jan Henk ^a   Ottervanger, Jan Paul ^a   Gosselink, A T Marcel ^a   de Boer, Menko Jan ^a   van't Hof, Arnoud W J ^a  

^a ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; PLACEBO; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; THROMBOCYTE AGGREGATION INHIBITION;

EID: 33646104183     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.05.025     Document Type: Article

References (23)

1. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention, results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
2. Barrett J.S., Murphy G., Peerlinck K., et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, in healthy men. Clin Pharmacol Ther 56 (1994) 377-388
3. Harrington R.A., Kleiman N.S., Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 76 (1995) 1222-1227
4. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
5. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
6. Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 (2001) 1915-1924
7. Sofer D., Moussa I., Karatepe M., et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 91 (2003) 872-875
8. Kabbani S.S., Aggarwal A., Terrien E.F., et al. Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 89 (2002) 647-650
9. Smit J.J.J., Hoorntje J.C.A., Miedema K., et al. Impaired platelet inhibitory effect of a single dose of acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers. Neth Heart J 12 (2004) 265-270
10. van't Hof A.W.J., Ernst N.M., de Boer M.J., et al. Facilitation of primary coronary angioplasty by early start of glycoprotein IIb/IIIa inhibitor: results of the ongoing tirofiban in myocardial evaluation (On-TIME) trial. Eur Heart J 25 (2004) 837-846
11. Ernst N.M.S.K.J., Suryapranata H., Miedema K., et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 44 (2004) 1187-1193
12. Carville D.G., Schleckser P.A., Guyker K.E., et al. Whole blood platelet function assay on the ICHOR point-of-care haematology analyzer. J Extracorpor Technol 30 (1998) 171-177
13. Lakkis N.M., George S., Thomas E., et al. Use of ICHOR-platelet works to assess platelet function in patients treated with Gp IIb/IIIa inhibitors. Cath Cardiovasc Interv 53 (2001) 346-351
14. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76 (1987) 142-154
15. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
16. van't Hof A.W.J., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 97 (1998) 2302-2306
17. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. Circulation 107 (2003) 32-37
18. Serebruany V.L., Steinhuble S.R., and Hennekens C.H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin?. Circulation 107 (2003) 1568-1569
19. Saw J., Steinhuble S.R., Berger P.B., et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo controlled clopidogrel trial. Circulation 108 (2003) 921-924
20. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
21. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with an acute myocardial infarction. Circulation 110 (2004) 1392-1397
22. Furman M.I., Barnard M.R., and Krueger L.A. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1002-1006
23. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111